Protagonist Therapeutics (PTGX) EBIT (2015 - 2026)

Protagonist Therapeutics has reported EBIT for 12 years, with the latest figure at -$3.6 million in Q1 2026.

• Quarterly EBIT rose 81.11% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$142.5 million (down 623.31% YoY) and the FY2025 annual result came in at -$158.1 million, down 162.54% from the prior year.
• EBIT advanced to -$3.6 million in Q1 2026 per PTGX's latest filing, from -$50.4 million in the prior quarter.
• Over five years, EBIT peaked at $206.3 million in Q1 2024 and troughed at -$50.4 million in Q4 2025.
• A 5-year average of -$7.9 million and a median of -$36.5 million in 2022 frame the typical range for EBIT.
• The sharpest annual moves came in 2024 and 2025: EBIT surged 672.75% in 2024, then plunged 139.72% in 2025.
• Over 5 years, EBIT stood at -$36.5 million in 2022, then surged by 163.12% to $23.0 million in 2023, then surged by 450.05% to $126.8 million in 2024, then slumped by 139.72% to -$50.4 million in 2025, then jumped by 92.76% to -$3.6 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$3.6 million, -$50.4 million, and -$46.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.